Anti-CD19, AlpHcAbs® Human antibody

Details and Advantages

                                                Applications:
                                                ELISA,Flow Cyt
                                            
                                                Reactivity:
                                                Human/Cynomolgus
                                            
                                                Conjugate:
                                                Unconjugated
                                            
                                                Advantages:
                                                High lot-to-lot consistency
Increased sensitivity and higher affinity
Animal-free production

Summary >

Description:
Anti-CD19, AlpHcAbs® Human antibody is designed for detecting human CD19 specifically. Anti-CD19, AlpHcAbs® Human antibody is recombinant fab of alpaca IgG1 fused to Human IgG1 Fc. Based on ELISA, Anti-CD19, AlpHcAbs® Human antibody reacts with human CD19, and has reactivity with cynomolgus CD19.

Immunogen: Recombinant human CD19
Host: Alpaca pacous
Isotype: Fab of alpaca IgG1 fused to Human IgG1 Fc(mutation)
Conjugate: Unconjugated
Specificity: Human CD19
Cross-Reactivity: Cross-reactivity with cynomolgus CD19
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles), Stable for 12 months at -20°C

Background:
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains. CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias. Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Besides being a signal-amplifying coreceptor for the B cell receptor (BCR), CD19 can also signal independently of BCR co-ligation and is a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
Using antibody with Fc(mutation), the background from Fc receptors will be eliminated.

Performance >

ELISA: 1:4,000-1:10000
Flow Cytometry：1:200-1:1000

Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.